Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Editas Medicine initiated with an Overweight at Cantor Fitzgerald » 16:13
01/31/23
01/31
16:13
01/31/23
16:13
EDIT

Editas Medicine

$9.85 /

+0.495 (+5.29%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Rick Bienkowski initiated coverage of Editas Medicine with an Overweight rating and $15 price target. The analyst believes the shares are well positioned to rally in the coming year due to favorable intellectual property positioning and expected clinical data updates. Follow-up data from the Phase 1 Ruby study in sickle cell disease in mid-2023 could strengthen clinical proof of concept for EDIT-301, the analyst tells investors in a research note.

ShowHide Related Items >><<
EDIT Editas Medicine
$9.85 /

+0.495 (+5.29%)

EDIT Editas Medicine
$9.85 /

+0.495 (+5.29%)

12/13/22 Citi
Editas Medicine initiated with a Neutral at Citi
12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
EDIT Editas Medicine
$9.85 /

+0.495 (+5.29%)

EDIT Editas Medicine
$9.85 /

+0.495 (+5.29%)

EDIT Editas Medicine
$9.85 /

+0.495 (+5.29%)

Over a week ago
Hot Stocks
Shoreline to acquire Editas' iNK cell franchise, related gene editing tech » 07:03
01/19/23
01/19
07:03
01/19/23
07:03
EDIT

Editas Medicine

$8.12 /

-0.22 (-2.64%)

Editas Medicine announced…

Editas Medicine announced that it has entered into a definitive agreement with Shoreline Biosciences for Shoreline to license Editas Medicine's proprietary SLEEK and AsCas12a gene editing technologies and acquire Editas Medicine's preclinical gene edited induced pluripotent stem cell derived natural killer cell programs and related manufacturing technologies. Shoreline Biosciences is a private biopharmaceutical company developing next-generation cellular immunotherapies based on iPSCs utilizing proprietary iNK and macrophage platforms. Under the terms of the agreement, Shoreline will obtain an exclusive license to Editas Medicine's interest in SLEEK gene editing knock-in technology for use in Shoreline's iNK platform and for oncology in its iMACs platform, and on a non-exclusive basis for iMACs in other indications. Shoreline will also receive a non-exclusive license for the use of Editas Medicine's engineered AsCas12a enzyme. As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine's preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. The acquisition of the Company's wholly owned oncology assets by Shoreline is part of Editas Medicine's strategic portfolio reprioritization, including its focus on the development of in vivo gene edited medicines. Shoreline will pay Editas Medicine an upfront payment at the close of the transaction. Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies. Evercore Group LLC served as financial advisor to Editas Medicine on the transaction.

ShowHide Related Items >><<
EDIT Editas Medicine
$8.12 /

-0.22 (-2.64%)

EDIT Editas Medicine
$8.12 /

-0.22 (-2.64%)

12/13/22 Citi
Editas Medicine initiated with a Neutral at Citi
12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
EDIT Editas Medicine
$8.12 /

-0.22 (-2.64%)

EDIT Editas Medicine
$8.12 /

-0.22 (-2.64%)

EDIT Editas Medicine
$8.12 /

-0.22 (-2.64%)

Hot Stocks
Editas Medicine provides update, to reduce headcount by approximately 20% » 08:43
01/09/23
01/09
08:43
01/09/23
08:43
EDIT

Editas Medicine

$9.00 /

+0.045 (+0.50%)

Editas Medicine announced…

Editas Medicine announced a strategic update, including portfolio reprioritization and research and development realignment. The Company's R&D efforts will narrow, focusing on hemoglobinopathies and in vivo discovery, as Editas Medicine will pursue and develop programs it believes have maximum probabilities of technical, regulatory, and commercial success. As a result of the strategic reprioritization, Editas Medicine's headcount is being reduced by approximately 20%, which is expected to extend the Company's cash runway into 2025. Editas Medicine's strategic changes include: Prioritizing resource allocation towards EDIT-301, the Company's lead clinical program for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. Discontinuing internal investments in the Company's inherited retinal disease programs, including EDIT-101 for Leber Congenital Amaurosis 10 and EDIT-103 for rhodopsin-associated autosomal dominant retinitis pigmentosa. Editas Medicine will seek partnerships for further development of its IRD programs. Discontinuing internal investments in the Company's wholly owned multiplexed edited induced pluripotent stem cell derived natural killer cell programs, including EDIT-202 for solid tumors. Editas Medicine will seek a partnership to continue development of the Company's iNK franchise. Restructuring the Company's research organization into two divisions: Drug Discovery for in vivo target identification, therapeutic asset creation, and translational research. Advanced Technology for in vivo targeted integration and targeted delivery. Developing milder patient preconditioning regimens for hematopoietic stem cell transplants. Developing next generation in vivo medicines, including in vivo editing of HSCs and other tissues. Editas Medicine will continue advancing its cellular therapy assets through partnerships, including continued development of alpha-beta T-cell medicines with Bristol-Myers-Squibb and gamma-delta T-cell medicines with Immatics N.V. The Company will also continue assessing additional collaboration opportunities to license Editas Medicine's intellectual property and proprietary technology.

ShowHide Related Items >><<
EDIT Editas Medicine
$9.00 /

+0.045 (+0.50%)

EDIT Editas Medicine
$9.00 /

+0.045 (+0.50%)

12/13/22 Citi
Editas Medicine initiated with a Neutral at Citi
12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
EDIT Editas Medicine
$9.00 /

+0.045 (+0.50%)

EDIT Editas Medicine
$9.00 /

+0.045 (+0.50%)

EDIT Editas Medicine
$9.00 /

+0.045 (+0.50%)

Over a month ago
Initiation
Editas Medicine initiated with a Neutral at Citi » 09:18
12/13/22
12/13
09:18
12/13/22
09:18
EDIT

Editas Medicine

$9.48 /

+0.015 (+0.16%)

Citi analyst Samantha…

Citi analyst Samantha Semenkow initiated coverage of Editas Medicine with a Neutral rating and $11 price target. The clinical-stage biotech company's CRISPR technology has "the potential to be transformative across multiple genetic diseases," but Editas has faced several leadership challenges and pipeline execution has lagged peers, Semenkow tells investors. The market was already fairly valuing EDIT-301 and pausing development of EDIT-101 in LCA10 has potential readthrough on feasibility for the remaining ophthalmology pipeline, said Semenkow, who expects shares to remain pressured.

ShowHide Related Items >><<
EDIT Editas Medicine
$9.48 /

+0.015 (+0.16%)

EDIT Editas Medicine
$9.48 /

+0.015 (+0.16%)

12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
EDIT Editas Medicine
$9.48 /

+0.015 (+0.16%)

EDIT Editas Medicine
$9.48 /

+0.015 (+0.16%)

EDIT Editas Medicine
$9.48 /

+0.015 (+0.16%)

Conference/Events
Editas Medicine to host conference call » 07:50
12/06/22
12/06
07:50
12/06/22
07:50
EDIT

Editas Medicine

$9.83 /

-0.425 (-4.15%)

Conference call to…

Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

Hot Stocks
Editas Medicine's EDIT-301 shows safety and efficacy in sickle cell disease » 06:36
12/06/22
12/06
06:36
12/06/22
06:36
EDIT

Editas Medicine

$9.83 /

-0.425 (-4.15%)

Editas Medicine announced…

Editas Medicine announced "positive" initial clinical data from the first two patients with sickle cell disease treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Patient 1 achieved neutrophil engraftment at 23 days after EDIT-301 infusion and platelet engraftment at 19 days after EDIT-301 infusion. Patient 2 achieved neutrophil engraftment 29 days after EDIT-301 infusion and platelet engraftment 37 days after EDIT-301 infusion. Additionally, neither patient has experienced any vaso-occlusive events since treatment with EDIT-301, at five and 1.5 months follow up, respectively. At five months post-treatment, the first patient treated with EDIT-301 has a total hemoglobin of 16.4 g/dL, a fetal hemoglobin (or HbF) of 45.4%, and a mean corpuscular HbF of 13.8 pg/red blood cell, exceeding the 10.0 pg/red blood cell threshold to suppress red blood cell sickling. Additionally, HbF increase in the first patient was highly pancellular, with F cells steadily increasing to reach greater than 95% of red blood cells. EDIT-301 was well-tolerated in the two patients and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. No serious adverse events occurred, and no adverse events reported were related to treatment with EDIT-301. The company expects to share further clinical updates in mid-2023.

ShowHide Related Items >><<
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

Conference/Events
Editas Medicine to host conference call » 04:55
12/06/22
12/06
04:55
12/06/22
04:55
EDIT

Editas Medicine

$9.83 /

-0.425 (-4.15%)

Conference call to…

Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

Conference/Events
Editas Medicine to host conference call » 17:26
12/05/22
12/05
17:26
12/05/22
17:26
EDIT

Editas Medicine

$9.83 /

-0.425 (-4.15%)

Conference call to…

Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link

ShowHide Related Items >><<
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

12/05/22 Credit Suisse
Editas Medicine assumed with a Neutral at Credit Suisse
11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

EDIT Editas Medicine
$9.83 /

-0.425 (-4.15%)

Initiation
Editas Medicine assumed with a Neutral at Credit Suisse » 16:10
12/05/22
12/05
16:10
12/05/22
16:10
EDIT

Editas Medicine

$9.86 /

-0.39 (-3.80%)

Credit Suisse analyst…

Credit Suisse analyst Richard Law assumed coverage of Editas Medicine with a Neutral rating and $13 price target. The analyst states that he is assuming a 70% probability of favorable final appeal ruling for Broad/MIT from the U.S. federal appeals court, which would give the company "monopolistic IP control of CRISPR/Cas9 editing in the U.S." Law further notes that he assigns "little value" to Editas' lead asset EDIT-301 as he does not believe that the company could demonstrate differentiated benefits that are "clinically meaningful".

ShowHide Related Items >><<
EDIT Editas Medicine
$9.86 /

-0.39 (-3.80%)

EDIT Editas Medicine
$9.86 /

-0.39 (-3.80%)

11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
11/18/22 Truist
Editas Medicine price target lowered to $35 from $80 at Truist
EDIT Editas Medicine
$9.86 /

-0.39 (-3.80%)

EDIT Editas Medicine
$9.86 /

-0.39 (-3.80%)

EDIT Editas Medicine
$9.86 /

-0.39 (-3.80%)

On The Fly
Biotech Alert: Searches spiking for these stocks today » 10:27
11/21/22
11/21
10:27
11/21/22
10:27
CTMX

CytomX Therapeutics

$1.73 /

+ (+0.00%)

, AGIO

Agios Pharmaceuticals

$28.81 /

+0.59 (+2.09%)

, LCTX

Lineage Cell Therapeutics

$1.45 /

+0.02 (+1.40%)

, EDIT

Editas Medicine

$10.62 /

-0.335 (-3.06%)

, IMUX

Immunic

$1.39 /

-0.015 (-1.07%)

, ABBV

AbbVie

$156.50 /

+1.5 (+0.97%)

, BMY

Bristol-Myers

$78.11 /

+0.64 (+0.83%)

, AMGN

Amgen

$289.92 /

+2.63 (+0.92%)

, RHHBY

Roche

$40.15 /

-0.03 (-0.07%)

, REGN

Regeneron

$730.87 /

-8.72 (-1.18%)

These names in the…

ShowHide Related Items >><<
RHHBY Roche
$40.15 /

-0.03 (-0.07%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

AGIO Agios Pharmaceuticals
$28.81 /

+0.59 (+2.09%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/10/22 JPMorgan
JPMorgan double downgrades 'show-me-story' CytomX Therapeutics
11/10/22 JPMorgan
CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan
07/11/22 Cowen
CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen
AGIO Agios Pharmaceuticals
$28.81 /

+0.59 (+2.09%)

11/17/22 Goldman Sachs
Agios Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
07/27/22 SVB Securities
Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
02/25/22 RBC Capital
Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
02/24/22 H.C. Wainwright
Agios Pharmaceuticals price target lowered to $96 from $98 at H.C. Wainwright
LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

11/01/22 Baird
Baird starts Lineage Cell Therapeutics with an Outperform, $5 price target
11/01/22 Baird
Lineage Cell Therapeutics initiated with an Outperform at Baird
06/14/22 B. Riley
B. Riley starts 'deep value play' Lineage Cell with Buy, $4 target
06/14/22 B. Riley
Lineage Cell Therapeutics initiated with a Buy at B. Riley
EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

11/18/22 Morgan Stanley
Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
11/18/22 BofA
Editas' EDIT-101 setback 'not the end of the story,' says BofA
11/18/22 RBC Capital
Editas Medicine price target lowered to $14 from $32 at RBC Capital
11/18/22 Truist
Editas Medicine price target lowered to $35 from $80 at Truist
IMUX Immunic
$1.39 /

-0.015 (-1.07%)

10/21/22 SVB Securities
Immunic downgraded to Market Perform from Outperform at SVB Securities
09/19/22 H.C. Wainwright
Immunic assumed with a Buy at H.C. Wainwright
06/02/22 Roth MKM
Roth suggests accumulating Immunic shares on pullback
06/02/22 Wedbush
Immunic price target lowered to $14 from $61 at Wedbush
ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

11/17/22 Credit Suisse
AbbVie initiated with an Outperform at Credit Suisse
11/08/22 Societe Generale
AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds
11/08/22 Societe Generale
AbbVie downgraded to Hold from Buy at Societe Generale
10/28/22 Piper Sandler
Piper keeps Overweight rating on AbbVie despite 'rough' Q3 report
BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
AMGN Amgen
$289.92 /

+2.63 (+0.92%)

11/17/22 Credit Suisse
Amgen initiated with an Underperform at Credit Suisse
11/08/22 Oppenheimer
Amgen price target raised to $300 from $290 at Oppenheimer
11/08/22 Truist
Amgen price target raised to $280 from $266 at Truist
11/04/22 Piper Sandler
Amgen price target raised to $278 from $265 at Piper Sandler
RHHBY Roche
$40.15 /

-0.03 (-0.07%)

11/15/22 Truist
Biogen price target raised to $350 from $265 at Truist
11/15/22 Truist
Eli Lilly price target raised to $421 from $400 at Truist
11/15/22 Stifel
Roche downgraded to Hold from Buy at Stifel
11/15/22 Cowen
Roche downgraded to Market Perform on 'bare' pipeline at Cowen
REGN Regeneron
$730.87 /

-8.72 (-1.18%)

11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
11/09/22 Truist
Regeneron price target raised to $856 from $790 at Truist
11/03/22 Piper Sandler
Regeneron price target lowered to $765 from $775 at Piper Sandler
10/31/22 EF Hutton
Regeneron initiated with a Buy at EF Hutton
RHHBY Roche
$40.15 /

-0.03 (-0.07%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

AGIO Agios Pharmaceuticals
$28.81 /

+0.59 (+2.09%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

RHHBY Roche
$40.15 /

-0.03 (-0.07%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

LCTX Lineage Cell Therapeutics
$1.45 /

+0.02 (+1.40%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

EDIT Editas Medicine
$10.62 /

-0.335 (-3.06%)

CTMX CytomX Therapeutics
$1.73 /

+ (+0.00%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

REGN Regeneron
$730.87 /

-8.72 (-1.18%)

IMUX Immunic
$1.39 /

-0.015 (-1.07%)

BMY Bristol-Myers
$78.11 /

+0.64 (+0.83%)

AMGN Amgen
$289.92 /

+2.63 (+0.92%)

ABBV AbbVie
$156.50 /

+1.5 (+0.97%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.